Pierre Fabre
New ways to care  

As its latest treatment for overactive bladder goes to market in Europe, Laboratoires Pierre Fabre marks 40 years of commitment to treating urinary disorders. Striking a perfect balance between long-standing therapeutic solutions and innovation, the laboratory’s ongoing ambition is clear: to improve quality of life for patients, alongside healthcare professionals. In 1982, Laboratoires Pierre Fabre made its first foray into urology, launching a treatment for moderate urinary disorders associated with benign prostatic hyperplasia. More than forty years later, that ground-breaking drug - marketed in 31 countries - remains a cornerstone of our brand portfolio. Still widely used in clinical practice, it illustrates the ongoing relationship of trust built up over several decades with urologists and general practitioners.

Lavaur (France), July 1, 2026 – Laboratoires Pierre Fabre announces the appointment of Venaïg  Solinhac as CEO of its Dermo‑Cosmetics and Personal Care division. In this role, she joins the executive committee of Laboratoires Pierre Fabre and reports to Eric Ducournau, Group CEO. Venaïg Solinhac brings more than 20 years of international experience driving growth and transformation for global leaders in consumer healthcare, consumer goods, and venture capital. She has held key executive positions at Kenvue, notably as Global Vice President of Baby Care (based in New York) and Vice President of Essential Health Asia Pacific (based in Singapore). There, she delivered tangible results: the global relaunch of Johnson’s Baby, the revitalization of Listerine in Asia‑Pacific, and the rollout of large-scale digital and commercial acceleration programs. Previously, she spent 15 years at GlaxoSmithKline Consumer Healthcare, where she held local, regional, and global leadership roles across four continents. There, she led transformative portfolio and digitalization initiatives, contributing to the growth of major brands such as Sensodyne, Panadol, Centrum, and Parodontax. As part of the Scale Up 2032 plan, Venaïg  Solinhac will lead the development and implementation of the strategy for Pierre Fabre’s Dermo‑Cosmetics and Personal Care division—Eau Thermale Avène, Ducray, A‑Derma, Klorane, René Furterer, Darrow, MÊME Cosmetics, and Pierre Fabre Oral Care. Backed by recommendations from dermatologists and pharmacists, these brands deliver expert, recognized solutions with high clinical value for sensitive and compromised skin (wound healing, eczema, acne, and the effects of cancer treatments), as well as leading solutions in oral health. In 2025, the business generated revenue of 1.711 billion euros (+2.6% vs. 2024), up +4.4% (at constant exchange rates). 

Back in 2009, Ducray was already pioneering  pharmacy refills with its iconic EXTRA-DOUX shampoo. Castres, 11June 2026 – To mark World Refill Day on 16 June, Laboratoires Pierre Fabre highlights the key role that reducing packaging and developing refill solutions in pharmacies has played for many years in its environmental responsibility approach. Driven by a portfolio of iconic dermo-cosmetic brands distributed worldwide — Avène, A-Derma, Ducray, Klorane and René Furterer —, Laboratoires Pierre Fabre has been implementing initiatives for over 15 years to reduce and limit the use of plastic, encourage reuse and guide consumers towards more responsible daily skincare habits, without compromising on quality or safety. 

The Avène catchment area and its thermal hydrosystem have been recognised as a site of geological interest within the Terres d’Hérault Geopark, designated a “UNESCO Global Geopark” Avène, 5th June 2026 – The “Terres d’Hérault” region has just been officially designated a UNESCO Global Geopark, in recognition of its exceptional geological wealth and the collective commitment of its stakeholders to the protection and promotion of this heritage.At the heart of this 2,046 km² area, comprising 58 remarkable geosites, lies the Avène catchment area, the place where Avène thermal spring water springs forth. This catchment area and its thermal hydrosystem are now recognised as a site of interest within the Terres d’Hérault Geopark. This decision reinforces the efforts of the API’A (Association pour la préservation de l’impluvium des eaux d’Avène) to promote understanding, preservation and enhancement of this exceptional area, which is now officially recognised. For over 50 years, Eau Thermale Avène brand has made understanding and preserving water resources one of its priorities. It has developed a robust scientific programme led by the Water Laboratory, a true multidisciplinary center of expertise dedicated to Avène thermal spring water: scientific and geological studies, mineral and microbiological analysis of the water, and pharmacological and clinical research.

Avène (France), 28 May 2026 – As part of its new industrial master plan, Laboratoires Pierre Fabre has reached a major milestone by announcing a strategic investment of nearly €50 million to transform and expand its production site in Avène-les-Bains (Hérault in France), which is fully dedicated to the manufacturing and packaging of Eau Thermale Avène products. This project reflects the company’s ambition to upgrade its sites into next generation factories that are more modern, more automated and less resource intensive, capable of sustainably supporting growth while reducing their environmental footprint.

Castres (France), May 26, 2026 - Pierre Fabre Participations, the Group’s parent holding company, has appointed Hervé Hoppenot as Chairman of the Board of Pierre Fabre SA. The Board of Directors, which met on May 21, approved this appointment. Hervé Hoppenot, who has served as a Board member of Pierre Fabre SA since January 15, 2024, succeeds Roch Doliveux, who has been appointed Vice Chairman of the Board. Hervé Hoppenot, 65, a dual French-American citizen, has spent most of his career in the United States. He served as Chair and CEO of the US biotechnology company Incyte from 2014 to 2025, gradually transforming it into a major player in the field of onco-hematology. Previously, he served as President of the Novartis Global Oncology franchise, where he oversaw one of the pharmaceutical industry’s largest portfolios of cancer prescription drugs. In addition to his new role at Pierre Fabre, Hervé Hoppenot also serves as Chair of the Board of Directors of the California-based biotech company Maze Therapeutics and as a director of two other biotech companies: Bicycle Therapeutics and N-Power Medicine. Pierre Yves Revol, Chairman of the Board of Pierre Fabre Participations, said:

In line with Pierre Fabre Laboratories' vision "Every time we care for a single person, we make the whole world better" the MSL (Medical Science Liaison) role is crucial in enhancing patient care. As a scientific bridge between the medical community and the Pierre Fabre Laboratories, the MSL combines pharmaceutical innovation with medical expertise to develop collaboration with healthcare professionals and optimize daily healthcare practices. The MSL's objectives can be achieved through various missions, including: Medical Education: promoting best practices for up-to-date patient management. Insight Collection: gaining a comprehensive understanding of patient treatment practices, organization, and patient journey. Data Needs Identification and participation to their generation to promote best practices for patient treatment. Support Clinical Development and Real-World Evidence Projects. Understanding patient needs.